This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Stock Reports for Cisco, SAP & Gilead
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems (CSCO), SAP (SAP) and Gilead Sciences (GILD).
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $63.99, moving +1.15% from the previous trading session.
Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment
by Zacks Equity Research
Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.
Why Gilead (GILD) Could Beat Earnings Estimates Again
by Zacks Equity Research
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Gilead-Galapagos Report Efficacy & Safety Results on RA Drug
by Zacks Equity Research
Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.
Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates
by Zacks Equity Research
Key highlights of the past week include label expansion of drugs, licensing deals and more.
Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan
by Zacks Equity Research
Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.
Novo Nordisk Focuses on Pipeline Development Amid Competition
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.
Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $62.23, marking a +0.99% move from the previous day.
AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug
by Zacks Equity Research
AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.
Enanta's Stock Down Despite NASH Drug Meeting Goal in Study
by Zacks Equity Research
Enanta (ENTA) posts favorable top-line data from the phase IIa study on its pipeline candidate EDP-305 for treating NASH. Albeit the study meets its goals, the stock declines in after-hours trading.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $64.20, marking a -0.56% move from the previous day.
Novo Nordisk's Semaglutide in Tablet Form Gets FDA Approval
by Zacks Equity Research
Novo Nordisk's (NVO) semaglutide in tablet form gets FDA nod as an adjunct to diet and exercise to improve glycaemic control in adults with type II diabetes mellitus.
Merck's Two HIV Drugs Get FDA Approval for Expanded Use
by Zacks Equity Research
Merck's (MRK) new HIV drugs, Pifeltro and Delstrigo, get FDA nod for use in treatment-experienced adults living with HIV-1 who are virologically suppressed.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $66.17, marking a +0.44% move from the previous day.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $68.08, moving +1.49% from the previous trading session.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $64.04 in the latest trading session, marking a +1.22% move from the prior day.
Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $63.54, moving -0.33% from the previous trading session.
Why Is Gilead (GILD) Down 2.9% Since Last Earnings Report?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Gilead & Galapagos Close Research & Development Agreement
by Zacks Equity Research
Gilead (GILD) closes collaboration agreement with Galapagos, per which the latter will receive an upfront license fee payment of $3.95 billion.
The Zacks Analyst Blog Highlights: Union Pacific, Lowe's, Gilead, Target and Emerson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Union Pacific, Lowe's, Gilead, Target and Emerson